FDA接受对Verastem新卵巢癌药的优先审查, FDA accepts priority review for Verastem's new ovarian cancer drug, boosting stock 21%.

维拉斯特姆瘤学公司的新药申请用于治疗复发性低度血清性卵巢癌已被FDA接受优先审查. Verastem Oncology's new drug application for treating recurrent low-grade serous ovarian cancer has been accepted for priority review by the FDA. 这项应用涉及将抗逆转录病毒药物和脱活性药物结合使用,如果获得批准,这将是这类癌症的首个具体治疗方法。 The application involves the combination of avutometinib and defactinib, which, if approved, would be the first specific treatment for this type of cancer. 这一消息导致Verastem的股票价格上涨21%,尽管今年股票下跌了50%以上。 This news led to a 21% increase in Verastem's stock price, though shares had fallen over 50% for the year. 预计FDA的决定将于2025年6月30日之前作出. The FDA's decision is expected by June 30, 2025.